UnitedHealth and CVS Seek Recusal of FTC Chair Lina Khan in Insulin Lawsuit

UnitedHealth Group and CVS Health have filed motions to have FTC Chair Lina Khan, along with Commissioners Rebecca Kelly Slaughter and Alvaro Bedoya, recuse themselves from an antitrust lawsuit, alleging they hold biases against pharmacy benefit managers (PBMs). This legal action arises from claims that the FTC has accused PBMs such as those owned by CVS and UnitedHealth of engaging in anticompetitive practices that inflate insulin prices through a rebate system[1][2]. The companies argue that past statements and official actions by Khan and her commissioners demonstrate a prejudgment of their liability[1][2]. This scenario is further complicated by public discourse involving influential figures regarding Khan's broader role in antitrust matters, with opinions divided on her approach to regulatory enforcement[2].
References
Explore Further
What are the specific statements or actions by Lina Khan that UnitedHealth and CVS claim demonstrate bias?
How might the recusal of FTC commissioners impact the outcome of the insulin lawsuit?
What evidence has the FTC provided to support their allegations of inflated insulin prices by PBMs?
How have political figures and public opinions influenced the debate over Lina Khan's antitrust approach?
What are the potential implications of this lawsuit on future regulatory practices for pharmacy benefit managers?